text:
Crest 3D White Professional Effects Whitestrips Review & Giveaway./
The holidays are almost here. It's that time of year when I want to look my best. I see friends and relatives that I rarely see. Beside primping my hair and wearing my newest holiday makeup, I want my teeth to look their whitest.
Imagine looking great but having yellow teeth? When it comes to your teeth, you can take precautions to avoid a yellow smile. The truth is that over time, your smile can yellow from everyday activities such as drinking coffee, tea or just indulging in your favorite meal. Yellow teeth is not an option for me. And it's a fact; if you're not whitening, you're yellowing. My answer to yellowing teeth? Crest 3D White Professional Whitestrips.
Imagine my daughters surprise when she came home from school and kept looking at me funny. You see, I played a little trick. I actually "yellowed" my teeth to see if anyone would notice. She was the first person to see me and she couldn't put her finger on it at first, but then finally said, "What happened to your teeth, Mom?". I told her I hadn't been whitening.
She basically told me to do something about it and quick. Ha! I had to simply brush off the yellowing agent to get my teeth looking "normal" again. But I also knew that I had to get my smile in better shape for the season, so I put these Crest 3D White Whitestrips to good use.
These new Whitestrips are super easy to use. I simply peel off the strips and carefully place them over my teeth. With the advanced seal no-slip technology, the whitestrips conform to my teeth and stay in place for 30 minutes. When the time is up, I simply remove them and brush my teeth. After 20 treatments (you can use them once a day for a 20 day treatment or twice a day for a 10 day treatment), teeth are noticeably whiter and brighter; ready for a great holiday smile. These strips work to remove over 10 years of set-in stains with the same enamel-safe ingredient that dentists use, but at a fraction of the cost. I am happy to report that they are gentle on my super sensitive teeth and gums too.
Look for the Crest 3D White Professional Effects Whitestrips at your favorite drugstore or mass retailer. They can also be purchased online at www.3DWhite.com. One kit retails for $49.99.
One lucky Beautiful Makeup Search reader will win one box (twenty treatments) of Crest 3D White Professional Effects Whitestrips. To enter, leave a comment on this post (by clicking the comments link above or filling out the form below) telling my why you want your teeth to look their best this holiday season.
Crest 3D Whitestrips Sweepstakes
The Crest 3D Whitestrips Sweepstakes (the "Sweepstakes") is intended for participation only in the United States (excluding Rhode Island) and shall be construed according to, and governed exclusively by, United States law. Do not participate in the Sweepstakes if you are not a legal resident of the United States (excluding Rhode Island) physically located in the United States (other than in Rhode Island) at the time of entry or do not fall within the eligibility requirements set forth in these official rules.
PROMOTION DESCRIPTION: The Sweepstakes begins on or about November 12, 2012 at 12:01 a.m. Eastern Standard Time ("EST") and ends on or about November 19, 2012 at 12:01 a.m. EST (the "Promotion Period"). By participating in the Sweepstakes, each entrant unconditionally accepts and agrees to comply with and abide by these Official Rules and the decisions of Beautiful Makeup Search/Crest("Sponsor"), which shall be final and binding in all respects. Sponsor reserves the right to modify or terminate sweepstakes if conditions arise that compromise its integrity or intended play.
ELIGIBILITY: Only legal residents of the fifty (50) United States and the District of Columbia (excluding Rhode Island) who are eighteen (18) years of age or older and located in the United States and the District of Columbia (excluding Rhode Island) at the time of entry are eligible to enter the Sweepstakes. Employees of Sponsor and Sponsor's advertiser partners and their respective parents, subsidiaries, affiliates, distributors, retailers, sales representatives, advertising and promotion agencies and each of their respective officers, directors and employees (and immediate family members and those persons living in the same household of any such officers, directors and employees) (collectively, the "Promotion Entities"), are ineligible to enter the Sweepstakes or win the prize. Subject to all applicable federal, state and local laws and regulations. Void in Rhode Island, Puerto Rico, all U.S. territories and possessions and overseas military installations, and where prohibited.
TO ENTER: Leave a comment on this page stating why you want your teeth to look their best this holiday season. Winner will be randomly chosen on or about November 19, 2012 and be notified by emai. Be sure to leave your email in the comment form where required, not in the comment. Winner has 48 hours to respond or prize will be forfeited. All decisions by the sponsor are final.
PRIZE DELIVERY: Sweepstakes prize will be delivered within 4 weeks of sweepstakes promotion period ending.
By entering this sweepstakes, you agree to all official rules.
Congratulations to commenter #56 Johanna whom was randomly selected as the winner!


text:
Just over a week before Round 1 of France's presidential elections, the race is tightening into a duel between Mr. Hot and Mr. Cool – Nicolas Sarkozy and François Hollande.
President Sarkozy is in full attack mode as Mr. Hot, doubling down, slashing, shooting in all directions, getting personal, scoffing at frontrunner Mr. Hollande, and warning that France faces a fearful future if he is not reelected.
Mr. Sarkozy's recent "Letter to the French People" raises perils on nearly every page: of Islamic radicals, unchecked immigration, and a France slipping into an economic crisis like that of Greece or Spain. Sarkozy now wants two TV debates before the runoff on May 6 that decides the presidency.
It's a hot attack style rarely seen in French politics. Sarkozy's numbers are not moving, and analysts say he needs momentum going into the second round.
"I'm going to win and I'll tell you why," Sarkozy said recently. "He [Hollande] is no good and people are starting to see it. Hollande is useless." Today, Sarkozy said his adversary's policies would bring a "massive crisis of confidence" in the economy.
Mr. Cool, the Socialist Hollande, continues on with a 7-10 point lead in the second-round May 6 vote that, in yesterday's opinion polls, appears to be cementing, if anything. He is playing things low key, appearing affable, making no fearful tirades, smiling a lot, and refusing to step into a muddy ring with Sarkozy, even when the latter smeared his journalist girlfriend as a "caviar liberal."
Mr. Cool's strategy is to make no mistakes and to outlast Sarkozy by gathering, rather than hunting, the center votes of a weary France he feels is ready for change.
Hollande is benefiting from Sarkozy's unpopularity and swimming with the tides of continued bad economic news, with high unemployment and no growth in the first quarter of 2012. He contends that Sarkozy's use of the terror and fear card will backfire, and that the French, after 11 years with Sarkozy as interior minister and then president, already see through it.
Hollande has in recent days taken pokes at Sarkozy, partly prodded by handlers who worry he needs to step up. At a rally yesterday, Hollande charged the current administration of "arrogance and conceit." He said Sarkozy's "excessive claims" were catching up to him, citing the president's assertion that he visited Fukushima after the tsunami, which did not happen.
"This is the first time in the history of the Republic that incumbent recounts a trip he has never taken," Hollande quipped in a comment reported in Le Nouvel Observateur.
Yet Hollande has been the only candidate to refuse an interview with Le Figaro, the center-right daily seen as pro-Sarkozy, saying he had the right to choose whom to speak with. Later, Hollande said he will talk to "all media" after Round 1.
France has 10 candidates vying for the April 22 elections, which narrow the campaign into a two-person race for May 6. Sarkozy and Hollande both are hovering at 28-29 points in current polling for Round 1. French Institute of Public Opinion (IFOP) polls show that the French see Sarkozy as more presidential than Hollande by a wide margin, but that Hollande is seen by a wide margin as more understanding of the French and sympathetic.
Biggest momentum is at opposite ends of the spectrum
The greatest movement or interest in the elections have been generated on the far-right and far-left wings of the political spectrum. Yet nationalist Marine Le Pen and former Trotskyite Jean Luc Mélenchon both hover around 15 percent and appear not to be in a position to enter the final round.
Recent days have witnessed a surge on the left, created by Mr. Mélenchon, who has held sensational rallies across the nation punctuated by red flags and the singing of the old communist "Internationale." What worries Hollande, his team says, is that the fiery Mélenchon could scare centrist voters away from the pragmatic and reasonable center-left that Hollande promises to govern from.
Analysts say Sarkozy's strategy is to turn the race into a bruising duel after April 22. His longstanding idea is to use April 22 to create momentum, a "strong dynamic," to surge into the lead May 6, says Eric Dupin, a political analyst for Rue 89 and author of "Travels in France."
Sarkozy was photographed Monday in athletic gear riding a racing bicycle uphill, a visual contrast with Hollande, who, while losing 40 pounds in the past year, usually appears in dress suits.
The French president must overcome a visceral unpopularity among French. His message of late has been that the French may not like him, but are safer with him. Sarkozy appeared at first to have benefited from the shocking killing rampage of a self-styled French-born Islamist radical in Toulouse, an event that extended into roundups of suspected Muslim radicals and the blocking of Islamic clerics from coming to France.
That seemed to change the focus of the campaign from French economic woes to the threat of Islam, though in recent days the fear factor seems to have abated as a benefit. Yesterday Sarkozy told French TV interviewers that the Toulouse shooting remained for him the central moment of the French campaign so far.
"Sarkozy is the man of the show … and at the moment, he tries to use all the issues he can find… to appear to be the boss. That's politics," says Karim Amellal, an Algerian-born novelist and media company owner. "It is not surprising [Sarkozy] is going after Islam and right wing topics. He had a perfect tragic event to work with, and he has used it," he says. "But we don't know the result yet."

subset: commoncrawl


text:
- When the reason for the change is unclear. Ambiguity--whether it is about costs, equipment, or tasks, change can trigger negative reactions among genealogists.
- When the genealogists have not been consulted about the change, and it is offered to them as an accomplished fact. People like to know what's going on, especially if their major activities may be affected. Informed genealogists tend to have higher levels of satisfaction than uninformed genealogists.
- When the change threatens to modify established patterns of working relationships between people.
- When communication about the change--timetables, personnel, monies, etc.--has not been sufficient.
- When the benefits and rewards for making the change are not seen as adequate for the trouble involved.
- When the change threatens the genealogist's status quo.
I would add that resistance to technological change is evident whenever a genealogist does not possess the basic skills, such as typing, manipulating a mouse, memory retention and reading comprehension that are necessary to feel like a successful technology user. If you would like to read another list of reasons see A. J. Schuler, Psy. D. "Reistance to Change." Dr. A. J. Schuler is an expert in leadership and organizational change. To find out more about his programs and services, visit www.SchulerSolutions.com or call (703) 370-6545. Schuler lists ten reasons for resistance that center around the way people feel.
Whatever the motivation for resisting change, it is a given fact that a significant portion of the genealogical community will continue to stay at whatever level of involvement they have obtained and will oppose any alteration in their own personal status quo.
Perhaps the problem with this situation is that it is viewed as a problem by others more accepting of technology. I had a short discussion today with a patron at the Mesa FamilySearch Library who was a professed Personal Ancestral File user and was inquiring which program would be the best one for her niece. In the context of the conversation, she adamantly refused to consider moving to another program. She was perfectly happy to consider the change for someone else, but not for herself.
I grew up when many women, especially mothers with small children, did not drive cars. There was obviously no compulsory reason that forced them into the marketplace to work and the family only owned one car and so the husband drove that one car to work. Even by 1960, only about 39% of the women in the U.S. were registered drivers. See Gender and Automobility. Selling Cars to American Women after the Second World War. My own mother did not learn how to drive until sometime in the 1950s. In addition, because of cultural bias, she never learned to type. Typing was seen as "menial" labor done by the "lower classes." Many people, especially those who are older, lack any formal training that included keyboarding. I happened to take typing in high school, but it was not required for graduation and it was considered a non-academic class, i.e. taken by those who were not college bound.
If you think about the sociological and cultural issues involved in the resistance to technology, you can see that the problem is really quite intractable and unsolvable in many cases. It would appear that the reasons for the divide between users and non-users of technology in genealogy is something we will have to live with until long after I am gone from this world.


text:
- 4 Beds
- 4 Full, 1 Half
- 4,557 +/- Sqft
Property TypeResidential – Single Family
SubdivisionBRECKENRIDGE SOUTH SUB
Listing Date10/07/18
Year Built2014
Lot Size0.93 Acres
Parking2 Car Garage
Property Description
Privately nestled, close to it all! New construction mountain modern home. Gorgeous glass chandeliers line the halls of this architect custom design home by Allen-Guerra. Open layout throughout the home. Exceptional master suite with double sided fireplace! Unbeatable kitchen with prepping/storage area and stone gas fireplace & high-end appliances. Office space, loft and 4 bedrooms. Move right in! Mother-in-law apartment with separate entrance. Outdoor BBQ and deck area on private wooded lot.
Presented By
- Bus Route
- In Town
- Mountains
- On Bus Line
- See Remarks
- Cable Tv
- City Sewer
- District Sewer
- Electricity
- Gas
- Phone
- Snow Removal
- Trash Pickup
- Radiant
- Dryer - Electric
- Washer
Financial Information
About Breckenridge
Victorian, family-oriented, and breathtaking natural beauty describe the classic Colorado ski town of Breckenridge. Enjoy countless outdoor activities, in both winter and summer, because Breckenridge averages over 300 days of sun each year and over 300 inches of snow each winter! With over one-million skier visits last year, Breckenridge is one of the most popular winter resorts in the country. Highlights include Breckenridge's historic main street, thrilling terrain parks, boutique restaurants and shops, and the Riverwalk Center. Throughout the year, cultural events like the Breckenridge Film Festival, the Backstage Theatre, weekend farmers markets and art festivals will entertain you. Quaint streets feature fine dining and endless shopping opportunities. With an array of ski-in/ski-out housing opportunities, you can throw open your front door and go. The resort ski runs come right down into town, so you can even ski home for lunch! A perfect mountain town!
Area Market Data
4 Beds 4.5 Baths
We get asked this question a lot. Below is a tool that gives you the ability to see what the market is like in your community. Find out what homes like your own are selling for right in your back yard. Simply enter in your address, choose the proximity of the search and find out market data for other homes that are selling near you.
While we'll provide you with plenty of information, this is a snapshot of your market data and there are real people behind the high-tech and automated tools. If you would like more detailed information or help in understanding the results we are here to help.
Until then, enjoy the tools!
The data relating to the real estate for sale on this website comes in part from the Internet Data Exchange program of the Vail Multi-List Service, Inc.
Copyright © 2019 Vail Multi List, Inc. (VMLS). The information displayed herein was derived from sources believed to be accurate, but has not been verified by VMLS. Buyers are cautioned to verify all information to their own satisfaction. This information is exclusively for viewers' personal, non- commercial use. Any republication or reproduction of the information herein without the express permission of the VMLS is strictly prohibited.
Listing courtesy of LIV SOTHEBY'S I.R.


text:
Monday, April 30, 2012
Saturday, April 28, 2012
PD or HD post cardiac surgery?
As I sat reviewing the chart my attending posed the following question "So is it reasonable to continue PD here in the unit or should we switch over to HD until she's extubated and clinically improving?"
Would the increased intra-abdominal pressure from PD lead to prolonged intubation time? Given the manipulation of the thoracic cavity was there a higher risk of dialysate leak through the diaphragm? Would we be able to provide adequate clearance and ultrafiltration with PD? Would the infection risk be higher for PD given the relative unfamiliarity of the nursing staff?
A recent article in Peritoneal Dialysis International comparing perioperative outcomes in patients on PD and HD post cardiac surgery sheds some light on the situation. In the study the Southern California Permanente Group at Los Angeles Medical Center looked back at 15 years of CABG and cardiac valve replacement surgeries in ESRD patients and compared a variety of outcomes between 36 patients on PD and 76 on HD.
There were no reported significant differences between the two groups at baseline including age, dialysis vintage, presence of diabetes, type of surgery and Charlson comorbidity index. The only statistically significant difference in terms of outcomes was a slightly longer median length of stay in the cardiac surgical unit for HD patients (4 vs 2 days) though the median total hospital length of stay between the two groups was no different (PD 9.5 days, HD 10 days).
There was trend towards more infections in the HD group (19% vs 6%) but this did not reach statistical significance. Median intubation time was the same between groups. Survival perioperatively (defined as during the hospital stay or within 30 days of operation) and at one and two years was similar between groups (PD 89%, 81%, 69%, HD 90%, 78%, 66%).
Conversion of PD patients to HD occurred in just 6% percent of patients. One for dialysate leak and another for uncontrolled azotemia. CRRT was needed in 1 HD patient due to hemodynamic instability.
The study doesn't answer the question of whether converting a patient on PD to HD or CRRT might improve outcomes but it does provide reassurance that PD patients don't have an excessive risk of dialysate leak or inability to achieve adequate clearance and ultrafiltration. It also shows that in general outcomes post cardiac surgery between PD and HD patients are similar.
In our patient we continued peritoneal dialysis using an automated cycler without difficulty. Over the weekend the covering team changed to HD via the arteriovenous graft over concern that PD might lead to a dialysate leak. Unfortunately the patient tolerated HD poorly with episodes of hypotension so we transitioned back to PD when we came back on. The rest of her hospitalization was without incident.
Thursday, April 26, 2012
Antibody-Mediated Rejection: Choose your weapons
Thursday, April 19, 2012
Beads on a String
A 41 year old gentleman with no past medical history presented to ER for nausea, vomiting and abdominal pain.
The commonest causes of renal infarcts are emboli from atrial fibrillation, infective endocarditis, or fat, renal artery or aortic dissection, fibromuscular dysplasia and vasculitis. Work-up including an EKG, ECHO, hypercoagulable panel and antiphospholipid antibodies were all negative. We performed an angiogram which showed diffuse visceral microaneurysms leading to a diagnosis of polyarteritis nodosa.
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that affects medium sized vessels. It was first described by Dr. Kussmaul and Dr. Maier in 1866. The incidence of the disease is 2 to 33 per million population, with a male to female ratio of 1.5:1. The major environment factor associated with PAN is HBV infection.
There are 5 variables that predict an increased risk of mortality in PAN (Five factors score FSS): 1) Proteinuria>1g/day
2) Renal insufficiency (Cr>1.58)
3) GI involvement (bleeding perforation, infarction or pancreatitis)
4) Cardiomyopathy
5) Central venous system involvement.
Without treatment, the 5 year mortality in patients with 0 risk factor is <12%, 1 risk factor 25% and 2 risk factors 56%. The standard treatment for FSS>1 is 12 months Cytoxan with steroids. Renal failure is rare in PAN patients and uncontrolled or relapsing vasculitis is the most common cause of death.
In our case, the patient was started on cytoxan and prednisone and his abdominal pain completely resolved. His creatinine unfortunately is still elevated and the plan is to continue with treatment for at least 6 months.
Posted by Jie Cui
Saturday, April 14, 2012
Palliative Care Experience of US Internal Medicine Subspecialty Fellows Survey
If you're interested, check it out here.
Friday, April 13, 2012
In "Nate's method"... what is the diagnosis?
Nate Hellman, the founder of this blog, was a personal friend. We trained together as MGH Renal Fellows. It has been three years since his passing. I often wonder how much he would have achieved by now. For sure, he would be on staff at Mass General and on faculty at Harvard Medical School. He would be well immersed in setting up his independent research career. He would be the caring doctor we all knew him to be. And most certainly, he would be writing this blog.
Those of us who knew him personally, know that Nate had the ability to write and release his brilliant thoughts to the world with little worry or inhibition, one of many traits I always admired in him. I think it came from his wonderful ability to laugh at himself and remain honest and real, no matter what. I have decided to start blogging, in an effort to remind myself, all of us here at MGH and all of you out there of "Nate's method." At least, I intend to try…
Here is the unknown case that was presented to me at the MGH Renal Grand Rounds this past Tuesday. One of our Renal Fellows, Dr. Jie Cui, presented the case, and will be blogging on her own thoughts on PAN soon (I have inside information here!):
41 yo M with no PMH was admitted with acute onset pain radiating to his R groin, 10/10, sharp and persistent. In the ER, he was found to have BP 188/116, mildly elevated Cr to 1.3, and elevated LDH 520. His CT showed bilateral renal infarcts and renal artery clot.
Home Medication: None
Physical Exam:
Vital Signs: T 98 HR 76 BP 120/90
GEN: Well appearing man in NAD
HEENT: MMM, oropharynx clear; PERRL.
Cards: NSR, RRR, normal S1, S2, no murmur/gallops/rubs
Chest: CTA B/L, no wheezing/rales/rhonchi
Abd: Soft/ND, + BS, RLQ (+) tenderness, no rebound/guarding, no bruits
Back: no CVA tenderness
Ext: normal tone, no edema, 5/5 muscle strength, no joint tenderness or deformities
Skin: no rash
Hypercoagulable work up (-) antiphospholipid antibodies (-), homocysteine (-)
ANA (-), ANCA (-), C3, C4 normal, Cryo (-),hepatitis (-), HIV (-),
Urine protein/cr: 0.12, 24 hour urine creatinine clearance: 54ml/min
Urine sediment: 1-2 WBC, 1-2 normal RBCs, no casts.
All Cultures were negative.
CT abdomen and pelvis:
1. Bilateral renal artery clot
2. There is a focal, geographic area of decreased perfusion involving the upper pole of the right kidney.
3. A focal area of cortical volume loss and decreased enhancement in the left kidney is also noted, suggestive of scarring.
Questions for the discussant:
1. What is the differential diagnosis?
2. What diagnostic procedure would you perform?
We discussed the following differential:
The differential of acute flank pain is:
Renal calculus – but no evidence on CT
Pyelonephritis – but cultures were negative
Other abdominal pathology as source of the pain – pancreatitis, cholecystitis – but no evidence on CT
Renal Infarct – yes, there is evidence for this on CT
This brings us to the differential for renal infarct:
Thromboembolic – from heart or aorta – but echocardiogram, including transesophageal echo with bubble study were negative, also cultures remained negative at all times
In situ thrombosis – no clear evidence for this
Renal artery occlusion from aortic dissection – no evidence for this on CT
Spontaneous or iatrogenic renal artery dissection – no evidence for this on CT
Fibromuscular dysplasia – no evidence for this based on history (no h/o HTN for example)
Segmental arterial mediolysis – possible, but again not supported by the CT
Complication of anti-phospholopid syndrome – but entire hypercoagulability panel was negative
Cocaine use – this could easily be the cause of this bilateral renal artery thrombosis, the patient continued to deny cocaine use, but this was strongly suspected, urine tox studies were apparently negative, but timing may have been the issue there...
Polyarteritis nodosa – interesting and also likely, the patient is HBV negative, but could be "idiopathic" PAN.
Given the above differential, a renal angiogram was performed which was read as consistent with medium vessel vasculitis, suggestive of PAN.
The patient was treated with steroids and cytoxan and is presently doing well, with creatinine stable in the 1.4 range and no new symptoms.
Still, we were left a bit dissatisfied with this outcome, as the diagnosis of PAN is not consistent with bilateral renal artery clot, which was clearly seen on CT in this patient.
I am still worried about cocaine use or another etiology…
Please comment and let us know your thoughts!


text:
Ian Martin talks to the animals
BAUHAU THE DACHSHUND. Woof! It's been a breakthrough year for the theory of Metarchitecture. People asked one other 'what does this mean? and through the medium of my friend and carer, theatrical agent Victoria Spong, I was able to answer 'it depends what you mean by "mean", woof!' It's this universality, this infinite flexibility, that has allowed Metarchitecture to flourish in salons and pop-up 'talking shops' across Britain.
I think one of our great challenges next year will be to bring Metarchitecture out of Post-Modernism's dark shadow. Let me say this clearly and unequivocally, woof, once again. The two movements are entirely unconnected. Post-Modernism's ironic bundling of the past has nothing to do with Metarchitecture's sarcastic fondling of the future. I wish people would stop saying it has; Ms Spong's mood is capricious at the best of times.
BESS OF HARDWICK THE BORDER COLLIE. In my gruff Cumbrian opinion, people should stop spouting pretentious nonsense about so-called 'architecture'. Especially them as lives in South. All 'architecture' means is 'how buildings look' right? Aye. Gruff. So instead of doing buildings that look like shite, we should do ones that just look nice instead.
It's time to stop fannying about with theories nobody outside a bloody Arts Council dinner party can understand. And back the non-cynical Looks Nice Theory devised by yours truly and my gaffer, the former epic space correspondent Darcy Farquear'say, who now manages a trope farm on the fells near Shap. Let's have some common sense at last, eh? Gruff.
PUSSY RIOT THE CAT. I was simultaneously proud and humble to be elected this year's winner of the General Styles Election. As a champion of Redactivism it will be my honour to serve the people of Britain and their pets for the next five years.
As both a cat and a muse for social commentator Emma Shoe I could perhaps be accused of playing a 'cat-and-muse' game with architectural politics, but let's be serious for a meowment. Why have people chosen Redactivism as the prevailing architectural mindset? Because in these dark days it is better to obliterate, to forget, than try to make sense of the world. As we all head further into the tunnel of recession, triple-dipping into blank, stale darkness like an Underground train, we need actively to discredit ALL architectural theories and simply wallow in collective bitterness. Meowy Christmas!
THE RT HON AENEAS UPMOTHER-BROWN'S BEES. It was with enormous, reverberating sadness that we bade farewell earlier this year to the coalition government. When our master left his post as architecture minister the country lost not only an eloquent 'voice of the beehive' but also the mind of that beehive. Us. We will miss the buzz of politics.
But we hope that our unique perspective as bees (not interested in non-bees, only bees matter, if you're not a bee you're clearly not doing the right thing) may have helped the Conservative party redefine itself for a modern, heartless Britain.
XKAV-8 THE POP-UP MOLE. Yo, dudes and bitches of contemporary architecture! Meet the freshest voice on the design scene! Yeah, I'm the new online mascot of the Royal Institute for the Pop-Uption of British Architects. Although not strictly speaking sentient, I am via the medium of Flash animation both lively and interactive. And being non-human means I can fully represent this most diverse of professions. Yes, I am 'fun' – watch my sexy wriggly dance for clients. But I have gravitas too – check out my cute little bowtie and spectacles. Oh, and I do a rap – rhyming 'wallet' with 'mallet'. Peace!
THE EMPRESS OF BLANDNESS. As the Prince of Wales' prize sow, I often have the good fortune to hear HRH's musings on the built environment at an early draft stage. There's certainly always something to chew over.
This year has been busier than ever as I was also appointed the Duchy of Cornwall's 'special adviser on corporation tax'. The job is a great deal less onerous than you'd imagine. Once a week an intern brings me all the correspondence from HM Revenue and Customs and I eat it. HRH is an enormously humane person, committed to the idea that we should all – prince or pig – fulfil our potential in life. Personally, I would like more understanding of the world. For instance, I still don't know what 'sausages' are.
Have your say
You must sign in to make a comment
Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions.
Links may be included in your comments but HTML is not permitted.


text:
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
-- Clinical Presentation in Waldenstrom's Macroglobulinemia Deemed "Best of ASH" --
Dec 10, 2013, 05:19 ET
NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).
"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."
Clinical Trial Presentation Highlights
Chronic Lymphocytic Leukemia
-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability of Response in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Leukemia (SLL) Patients in an Open-Label Extension Study
Susan O'Brien, M.D., Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
A long-term analysis of Phase 1/2 studies of single agent ibrutinib in 148 patients with CLL/SLL aimed to evaluate safety based on time on therapy, summarize safety findings in both the treatment-naive and relapsed/refractory (R/R) populations and assess overall response rate (ORR) and duration of response (DOR). The results showed that the percentage of patients who experienced a grade 3 or higher serious adverse event (SAE) declined over time from 43% within the first year of study treatment to 32% after the first year of treatment. Grade 3 or higher adverse events (AEs) and SAEs considered to be related directly to ibrutinib also declined notably compared to the first year of treatment: 24% and 8%, respectively, to 7% and 0%. The most frequent grade 3 or higher adverse events regardless of relationship to study drug were pneumonia (16.9%), hypertension (13.5%), neutropenia (11.5%), thrombocytopenia (7.4%) and diarrhea (5.4%).
Based on these patients the ORR was determined at 80.6% for treatment-naive patients, and 83.8% for R/R patients. The ORR plus partial response with lymphocytosis was 87.1% in the treatment-naive population and 88.9% in the R/R population. Median DOR was not reached in either population. At 30 months, 95.8% of treatment-naive and 69.7% of R/R responders were alive without disease progression.
-ORAL PRESENTATION- CLL Abstract #675:
Ibrutinib In Combination With Rituximab (iR) is Well Tolerated and Induces a High Rate of Durable Remissions in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients
Jan A. Burger, M.D., Ph.D., Department of Leukemia, MD Anderson Cancer Center, Houston, TX
The objectives of this study were to assess the activity and tolerability of ibrutinib and rituximab in combination, in high-risk CLL patients. The study included 40 patients with CLL, with a median of two prior therapies. Twenty of the patients had del 17p mutations and 13 patients had del11q. Thirty-four patients (85%) achieved a partial response (PR), and four (10%) achieved a complete response (CR), leading to an ORR of 95%. One of four CRs were negative for minimal residual disease (MRD) by flow cytometry.
The most common AEs related to treatment, all grade 1 or 2, were diarrhea (n=17), bruising/rash (n=14), arthalgia (n=13), nausea/acid reflux (n=10) and upper respiratory infection (n=9). The most common grade 3 or higher AEs related to treatment were lung infection (n=4), peripheral neuropathy (n=3), neutropenia (n=2), mucositis (n=2) and increased ALT (n=1).
Questionnaires revealed improved overall health and quality of life after 6 months, based on Quality of Life questionnaire (EORTC-QOL-v.3), with 89% of patients reporting a high quality of life score (6 to 7) compared to 46% at baseline and patients achieved a statistically significant increase in body weight.
-POSTER PRESENTATION- CLL Abstract #2872:
Changing the Treatment Paradigm for Previously Treated Chronic Lymphocytic Leukemia Patients with Del(17p) Karyotype
Deborah M. Stephens, D.O., Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
This retrospective analysis aimed to describe the success of treatment of del 17p patients on clinical trials at The Ohio State University (OSU). The study reviewed records of 174 CLL patients with del 17p who had received prior therapy.
At patients' first treatment at OSU (OSU Tx1), 16% (n=27), 33% (n=58), and 51% (n=89) of pts received an ibrutinib-based therapy, cyclin-dependent kinase inhibitor-based therapy (CDKi), or other therapies (O), respectively.
The ORR was significantly different among groups at 56%, 45%, and 24% in the ibrutinib, CDKi, and O groups, respectively. 12-month progression free survival (PFS) estimates were 77%, 38%, and 17% in the ibrutinib, CDKi, and O groups, respectively. 12-month overall survival (OS) estimates were 81%, 78%, and 58%. Notably, age did not correlate with response, PFS, or OS.
-ORAL PRESENTATION- CLL Abstract #673:
Single Agent Ibrutinib Achieves Equal Responses in CLL Patients With and Without Deletion 17p
Mohammed Farooqui, DO, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD
This phase 2, single center, study of ibrutinib as a single-agent aimed to address the role of ibrutinib in the treatment of CLL patients with del 17p, regardless of their prior treatment history. The study enrolled 29 patients with del 17p, and 24 elderly patients without del 17p (NL 17p). Fifteen of the del 17p patients and eight of the NL 17p patients were treatment naive. The primary endpoint of the study was response after 6 months, assessed by computed tomography (CT) scans, bone marrow biopsies, and routine clinical and laboratory studies.
At six months, 47 patients were evaluable. Of the patients with del 17p, 53% achieved a PR and 43% achieved a PRL, compared to 82% PR and 9% PRL among the NL 17p patients. The apparent difference in response rates is due to slower clearance of the treatment-induced lymphocytosis in the del 17p patients; however, the clinical benefit and disease control in all tissue sites was equal for both cohorts of patients. Twenty-month PFS was 100% in the NL 17p cohort, and 85% in the del 17p cohort.
The most common AEs, predominantly grade 1, were diarrhea (41%); arthralgia (30%); rash (27%); fatigue and bruising (20% each); and cramps (18%). The most common grade 3 or higher AEs were lung infection (5%) and rash (2%).
-ORAL PRESENTATION- CLL Abstract #525:
Ibrutinib in Combination With Bendamustine and Rituximab Is Active and Tolerable in Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study
Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA
The primary objective of this study of 30 patients was to evaluate the safety of ibrutinib in combination with bendamustine and rituximab in patients with R/R CLL, and the secondary objectives were to evaluate the ORR and PFS. The observed safety profile for this novel combination was generally consistent with the safety profile of bendamustine and rituximab. The most frequently reported treatment-emergent AEs, regardless of attribution were predominantly grade 1 or 2, including diarrhea (70%), nausea (67%), fatigue (47%), neutropenia (40%) and upper respiratory tract infection (37%). The most frequently reported grade 3 or higher AEs were neutropenia (40%), rash and fatigue (10%each), thrombocytopenia and cellulitis (7% each), and febrile neutropenia (6%). Transient treatment-related lymphocytosis occurred less frequently in this combination than with ibrutinib monotherapy (Byrd et al, NEJM 2013).
With a median duration of treatment of 16 months, the ORR was 93.4% (28 out of 30 patients, including 5 CRs and 3nPRs), and one additional patient achieved a partial response with lymphocytosis. The median PFS has not been reached, and responses appeared to be independent of high-risk features. This combination is currently under investigation in a global Phase 3 trial.
Waldenstrom's Macroglobulinemia
-BEST OF ASH ORAL PRESENTATION- Abstract #251:
A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia
Steven Peter Treon, M.D., M.A., Ph.D., Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA
This study evaluated the efficacy and tolerability of ibrutinib in 63 patients with relapsed or refractory WM, and examined the impact of MYD88 L265P and WHIM-like CXCR4 mutations on ibrutinib response. With a median follow-up at 9 cycles (9 months), the best ORR (minor response or better, using consensus criteria adapted from the 3rd International Workshop on WM) was 83%. Six patients had a very good partial response, 34 achieved a PR, and 12 achieved a minor response (MR), with a major response rate (PR or better) of 64%. Ten patients showed stable disease. In patients who underwent tumor sequencing, attainment of major responses was impacted by mutations in CXCR4, but not MYD88 L265P.
The most common Grade 2 or higher treatment related AEs were neutropenia (n=12); thrombocytopenia (n=10); bleeding (n=5); and pneumonic infection, anemia and tachyarrhythmia (n=3 each). The most common grade 3 or higher treatment-related AEs were neutropenia (n=9) and thrombocytopenia (n=7). After a median follow up of 9 cycles, fifty-five patients (87.3%) continue on treatment.
Non-Hodgkin's Lymphoma
-ORAL PRESENTATION- Abstract #852
Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Treatment-Naive Patients With CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)
Anas Younes, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
R-CHOP is a standard of care in a number of the most common B-cell malignancies, including several NHL subtypes, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). This study was an open-label, nonrandomized, multicenter study consisting of 2 parts: dose escalation in patients with DLBCL, MCL and FL (Part 1) and dose expansion only in DLBCL patients (Part 2). The primary objective of this phase 1B study in 33 patients was to determine the recommended phase 2 dose and dose-limiting toxicities of ibrutinib in combination with R-CHOP. Secondary objectives were to evaluate safety, ORR and pharmacokinetics. The results below focus on the 24 DLBCL patients across Parts 1 and 2 of the study.
Across Parts 1 and 2 (n=24), the most common all-grade treatment-emergent AEs (> 25%) were neutropenia (70.8%), nausea (66.7%), vomiting (66.7%), thrombocytopenia (58.3%), fatigue (50%), constipation (41.7%), anemia (41.7%), and diarrhea (33.3%). The most common Grade 3 or higher treatment-emergent AEs were neutropenia (66.7%), thrombocytopenia (16.7%), febrile neutropenia (16.7%), anemia (12.5%) and hypotension (8.3%).
The ORR for all evaluable patients across Parts 1 and 2 was 91.7%, with 83.3% of patients achieving a CR, and 8.3% achieving a PR.
Pre-Clinical and Non-Clinical Presentation Highlights
During the ASH meetings this year a total of 33 pre-clinical and non-clinical presentations were presented, 7 of these were oral and 26 poster presentations. The data presented provides further insights into ibrutinib including: 1) the potential reconstitution of the immune system in CLL patients 2) valuable findings of mechanism of action of ibrutinib 3) the apoptotic effect (cell death) of ibrutinib in both the tissue and blood for CLL cells and 4) many models illustrating combinations with many other therapies. Below are a select, few abstracts:
Poster Abstract #4182: In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity
Georg Aue, MD, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
This study demonstrated ibrutinib's impact on the recovery of humoral immunity equally amongst treatment naive and relapsed refractory CLL patients. Consistent with other reports we see little change in IgG levels in the first 12 months. Importantly, ibrutinib leads to a significant increase in both IgA and IgM serum levels, suggesting a beginning recovery of humoral immunity. The reduction of clonal light chains, a tumor marker, correlates with clinical response. In contrast, the increasing levels of the non-clonal light chain may herald a recovery of the normal B-cell (and possibly plasma cell compartment) raising the possibility that ibrutinib may selectively target CLL cells while allowing the re-growth of normal B-cells.
Poster Abstract #4166: Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib
Dominik Wodarz, Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, CA
This two-compartment analysis provides greater insight into ibrutinib's mechanism of action in CLL. During ibrutinib therapy, on average 1.7% (± 1.1%) of the cells die per day in the blood, while in tissue 2.7% (± 0.99%) of the cells die per day. These death rates during treatment are approximately 3-5 times higher than those estimated in previous studies in the absence of treatment. The amount of CLL cells from the tissue that was redistributed into the blood during ibrutinib therapy accounted for an average of 23.3% (± 17%) of the calculated total tissue disease burden. Therefore the majority of tissue shrinkage is attributed to apoptosis of the CLL cells in the tissue. These findings indicate that generally a relatively small fraction of the total tissue CLL cell burden is re-distributed into the blood during ibrutinib therapy, and that a significant amount of drug-induced cell death occurs in tissue compartments.
Oral Abstract #118: Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways
Sarah E. M. Herman, PhD, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Prior studies have shown that CLL cells in the lymph node and bone marrow microenvironments demonstrate higher levels of BCR and NF-κB signaling as well as increased cell activation and proliferation (Herishanu et al., Blood 2011). This study's goal was to determine the in vivo effect of ibrutinib on tumor cell activation and proliferation in these microenvironmental niches. Analysis of bone marrow from two cycles of treatment shows that ibrutinib effectively inhibits BCR, NF-κB, and ERK signaling. This occurs very quickly as demonstrated in the lymph node and is sustained on treatment as shown in the bone marrow. The strong and sustained reduction in proliferation and activation of CLL cells in the tissue microenvironment suggests that BTK is indeed a central hub mediating the nourishing and protective effects of the tumor microenvironment.
About IMBRUVICA
IMBRUVICA (ibrutinib) is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established. For more information about IMBRUVICA, including the full prescribing information, please visit www.IMBRUVICA.com. IMBRUVICA is a first in class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to grow and divide uncontrollably. It is one of the first medicines to receive FDA approval via the new Breakthrough Therapy Designation pathway, enabling Pharmacyclics to rapidly bring this medicine to patients in need.
To date, nine Phase III trials have been initiated with IMBRUVICA and a total of 38 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize IMBRUVICA.
About Pharmacyclics
Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at www.pharmacyclics.com.
The following safety information is described in the package insert for the use of IMBRUVICA in patients with MANTLE CELL LYMPHOMA who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.
Hemorrhage - 5% of patients with MCL had ≥ Grade 3 bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria). Bleeding events including bruising of any grade occurred in 48% of patients with MCL treated with 560 mg daily. The mechanism for the bleeding events is not well understood. Consider the benefit-risk of IMBRUVICA in patients requiring antiplatelet or anticoagulant therapies and the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre and post-surgery depending upon the type of surgery and the risk of bleeding.
Infections - Fatal and non-fatal infections have occurred. At least 25% of patients with MCL had infections ≥ Grade 3, according to NCI Common Terminology Criteria for Adverse Events (CTCAE). Monitor patients for fever and infections and evaluate promptly.
Myelosuppression - Treatment-emergent Grade 3 or 4 cytopenias were reported in 41% of patients. These included neutropenia (29%), thrombocytopenia (17%) and anemia (9%). Monitor complete blood counts monthly.
Renal Toxicity - Fatal and serious cases of renal failure have occurred. Treatment-emergent increases in creatinine levels up to 1.5 times the upper limit of normal occurred in 67% of patients and from 1.5 to 3 times the upper limit of normal in 9% of patients. Periodically monitor creatinine levels. Maintain hydration.
Second Primary Malignancies - Other malignancies (5%) have occurred in patients with MCL who have been treated with IMBRUVICA, including skin cancers (4%) and other carcinomas (1%).
Embryo-Fetal Toxicity - Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. Advise women to avoid becoming pregnant while taking IMBRUVICA. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
The most commonly occurring adverse reactions (≥ 20%) in the clinical trial were thrombocytopenia*, diarrhea (51%), neutropenia*, anemia*, fatigue (41%), musculoskeletal pain (37%), peripheral edema (35%), upper respiratory tract infection (34%), nausea (31%), bruising (30%), dyspnea (27%), constipation (25%), rash (25%), abdominal pain (24%), vomiting (23%) and decreased appetite (21%).
*Treatment-emergent decreases (all grades) of platelets (57%), neutrophils (47%) and hemoglobin (41%) were based on laboratory measurements and adverse reactions.
The most common Grade 3 or 4 non-hematological adverse reactions (≥ 5%) were pneumonia (7%), abdominal pain (5%), atrial fibrillation, diarrhea (5%), fatigue (5%), and skin infections (5%). Treatment-emergent Grade 3 or 4 cytopenias were reported in 41% of patients. Ten patients (9%) discontinued treatment due to adverse reactions in the trial (N=111).
The most frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%). Adverse reactions leading to dose reduction occurred in 14% of patients.
CYP3A Inhibitors - Avoid concomitant administration with strong or moderate inhibitors of CYP3A. If a moderate CYP3A inhibitor must be used, reduce the IMBRUVICA dose.
CYP3A Inducers - Avoid co-administration with strong CYP3A inducers.
SPECIAL POPULATIONS - Hepatic Impairment - Avoid use in patients with baseline hepatic impairment.
Because everyone is different, it is not possible to predict what side effects any one patient will have. Patients with questions or concerns about side effects should talk to their doctor.
Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch.
For more information please read the IMBRUVICA Full Prescribing Information at www.IMBRUVICA.com.
NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.
SOURCE Pharmacyclics, Inc.


text:
The heart has four chambers. It has two upper chambers (atria) and two lower chambers (ventricles). Electrical signals regulate the heart beat. The signals also help the atria and ventricles work together in the same rhythm. The blood from the atria is pushed into the ventricles and leave the heart to circulate to the rest of the body.
Atrial flutter is a type of abnormal fast beating ( arrhythmia) in the atria. These fast beats make it difficult for the atria to pushing all the blood into the ventricles. As a result, the ventricles push less blood through the body.
Atrial flutter may be an acute or chronic disorder that comes and goes. Atrial flutter is not usually life-threatening when it is treated. However, it may increase your risk of developing blood clots and stroke.
This condition can be treated. Contact your doctor if you think you may have atrial flutter.
Anatomy of the Heart
Copyright © Nucleus Medical Media, Inc.
Atrial flutter may be caused by the following:
- Coronary artery disease
- Heart surgery–atrial flutter is most common during the first few weeks after open-heart surgery
- Disease in other parts of the body that affects the functioning of the heart, such as the lungs
- Using substances such as caffeine, alcohol, diet pills, or certain types of prescription or over-the-counter medication that affect the electrical impulses of the heart
- Stress and anxiety
Risk Factors
Risk Factors
Factors that increase your chance of atrial flutter include:
- Heart disease
- Heart surgery
- History of high blood pressure
- Abnormalities of the heart or heart valves (hypertrophy, mitral valve prolapse)
- Overactive thyroid gland ( hyperthyroidism)
- History of chronic lung disease ( emphysema, chronic obstructive pulmonary disease [COPD])
- High levels of stress or anxiety
- Chronic use of caffeine, alcohol, diet pills, or certain types of prescription or over-the-counter medication (such as cold medicines)
Atrial flutter is more likely to develop in older adults.
Atrial flutter does not always produce symptoms. However, symptoms, when present, may include:
- A fluttering or tremor-like feeling in the chest
- Rapid heart beat or pounding sensation in the chest (palpitations)
- Pressure or discomfort in the chest
- Shortness of breath
- Anxiety
- Lightheadedness or fainting
Your doctor will ask about your symptoms and medical history. A physical exam will be done. Your doctor may also recommend that you see a cardiologist or arrhythmia specialist. This type of physician may be found in a larger hospital.
Your doctor may need pictures of your heart and information about how it functions. This can be done with:
The goal of treating atrial flutter is to slow down the electrical impulses that are sent from the atria to the ventricles. Treatment aims at restoring normal rhythm and preventing future episodes. Talk with your doctor about the best treatment plan for you. Treatment options include the following:
Medication may be given to slow the rapid heart rate and change the atrial flutter to a normal rhythm. These medications may include:
- Beta-blockers
- Digoxin
- Adenosine
- Nonhydropyridine calcium channel antagonists
Other medications called antiarrhythmics may be used to change the rhythm back to normal. They may also help your heart maintain a normal rhythm.
An external defibrillator is applied to the chest. It uses electrical current to shock the heart back to its normal rhythm.
Ablation Therapy
Ablation can be performed during an EP study on patients with recurring atrial flutter that cannot be controlled with medications. Using the same catheters, an area of the heart where an abnormal electrical rhythm is generated can be destroyed. This can be a cure for atrial flutter.
Blood Thinners
Blood thinners are an important therapy to prevent blood clots that can cause strokes or other serious complications. They can be used on those who have recurrent atrial flutter. They can also be used on those who are at an increased risk.
To help reduce your chance of atrial flutter:
- Reduce or eliminate your use of caffeine, stimulants, alcohol, nicotine, certain medications, or recreational drugs
- Obtain treatment for any other heart or lung disease
- Reduce your levels of stress and anxiety
- Check with your doctor before taking any new medications, herbs, or supplements
Heart Rhythm Society http://www.hrsonline.org/
Heart and Stroke Foundation http://www.heartandstroke.com
Updated October 31, 2012. Accessed November 9, 2012.
Atrial flutter. Heart Rhythm Society website. Available at
Accessed November 9, 2012.
Lee KW, Yang Y, et al. Atrial flutter: a review of its history, mechanisms, clinical features, and current therapy. Curr Prob Cardiol. 2005;30(3):121-167.
Last Updated: 12/20/2014


text:
Jan. 28, 2010
NORTH DARTMOUTH, MA-The University of Massachusetts Dartmouth's swimming team fell to visiting Worcester Polytechnic Institute at the Tripp Athletic Center Thursday evening. The WPI men won, 123-118, and the women prevailed, 138-103.
The men's meet went down to the final event, with the Engineers winning the 200 yard freestyle in 1:32.90. For the men, senior Matt Fahey (New Bedford, MA/Middleboro HS) won both the one-meter diving (229.40 points) and the three-meter diving competition (259.80 points), junior Craig Johnson (Acushnet, MA/New Bedford HS) took the 50 yard freestyle in 22>27 seconds, freshman Jake Pesante (Wakefield, RI/South Kingston HS) won the 200 freestyle in 1:50.23, junior Steve Szarek (Middletown, CT/Middletown HS) won the 200 breaststroke in 2:24.80, and the 200 yard medley relay team of freshman Chris Dodge (Holden, MA/Wachusett Regional HS), freshman Matt Dean (Londonderry, NH/Londonderry HS), Johnson and Szarek was victorious in 1:44.31.
For the women, sophomore Kim Moore (Billerica, MA/Billerica HS) and senior Kathleen Foley (Haverhill, MA/Haverhill HS) were both double winners. Moore won the 500 yard freestyle in 5:40.98 and the 1000 freestyle in 11:31.63, while Foley took the 200 individual medley in 2:23.68 and the 100 breaststroke in 1:13.10. Freshman Morgan Cooper (Sunderland, MA/ Frontier Regional HS) won the 50 freestyle in 26.68 seconds, while freshman Cecelia Rius (Rockville, MD/Richard Montgomery HS) took the one-meter diving competition with 203.25 points.
"We had several people who were unable to compete because they were ill, but we had some strong swims," said UMass Dartmouth Head Coach Cathy Motta. "We are tired. Once we get through this weekend, we'll get ready for our final regular season meet, and we'll get ready to taper for the championships."
UMass Dartmouth's men are now 3-3, while the women are 4-5. The WPI men are 2-4 and the women are 2-5.
The Corsairs will return to action when they host Plymouth State Saturday. WPI will visit Clark next Wednesday night


text:
Lighting work means different things to different electrical contractors. It can be as basic as wiring a string of 2×4 fluorescent troffers for a small office building or as complex as in-stalling an intricate fiber-optic lighting system to illuminate a Disney theme park (see Staff Writer Amy Fischbach's cover story, "An electrifying California adventure," on page 12).
Make no mistake about it — lighting can be big business for electrical contractors. According to the Department of Energy, lighting accounts for about 25% of the nation's total electrical bill. The Environmental Protection Agency (EPA) estimates that for businesses, the lighting load can be even higher. Sparked by utility power shortages and the resulting end user demand to reduce electrical loads by retrofitting lighting systems, the call by customers for energy conservation may finally be hitting the high note that its proponents have wanted to hear for years.
Energy-efficient electrical products are often a tough sell in the electrical market. Manufacturers of lamps, ballasts, lighting fixtures and lighting controls have been cranking out ever-more efficient lighting products since the days of the first oil crisis, more than 25 years ago. But due to concerns over the higher upfront price tags of these products, end users often tuned out talk about proven total installed cost savings produced by the more energy-efficient products.
Utility rebates created what turned out to be artificial demand for these products in the early 1990s. Once utilities stopped offering rebates, many customers again lost interest in energy efficiency. Even federal legislation that banned the manufacture of some of the least efficient lamps and ballasts hasn't created the expected surge of demand for more efficient products.
Most lighting experts agree that the move toward more efficient products will continue to grow slowly but surely. One of the key elements in this evolutionary process will be the ANSI/ASHRAE/IESNA 90.1-1999 standard. This is a building code spreading toward national acceptance that, in part, requires the use of more efficient light sources and luminaires, sets a standard for lighting power density (LPD) in watts per square foot, and requires the use of lighting controls to reduce illumination in unoccupied rooms.
You can learn how this standard could create new business for your company in a special report in this issue, "Green Lighting for the New Millennium" (page 43). Published in cooperation with Intertec Publishing Corp.'s Lighting Dimensions and EC&M magazines and written in part by CEE News' Contributing Editor Joe Knisley, this article will help you understand which lighting products will offer the type of energy savings that this standard requires.
If you are looking for more information on the ANSI/ASHRAE/IESNA 90.1-1999 standard or want to learn about other areas of the lighting market, here are my picks for five places to start your search:
Illuminating Engineering Society of North America, www.ieasna.org
The Lighting Research Center, www.lrc.rpi.edu
International Association of Lighting Designers, www.iald.org
Another can't-miss opportunity to learn more about the lighting market is to attend this year's LightFair 2001 trade show in Las Vegas, May 30-June 1. Check out www.lightfair.com for registration information.


text:
Where's the best place to get a burger in your area?
The winners of the best burgers in the country have been crowned at the National burger Awards 2016.
Joe Leckie, of burger joint Mac & Wild has been crowned the burger champion of Great Britain, with his signature 'Venimoo' burger earning him the grand prize of £1,000.
The event also saw two other chefs win accolades. Simon Xavier from Chiquito won the Technical Burger award, which involves the 16 National Burger Awards finalists creating a burger out of ingredients that are provided to them on the day; and David Fernandez from Stock Burger Co. claimed the Signature Burger award with his Ox Jus Burger.
Joe Leckie, winner of the National Burger Awards 2016, comments: "I'm really shocked to be honest. I'm used to doing 200 burgers at lunchtime, but it was a different type of pressure with everyone looking at you. In the restaurant, I'm in my own little zone and I can do what I want, but when people are watching you it's very different.
"Competitions like this are really important. It was great just to be in the final with so many different chefs – it makes you a lot more aware of what everyone else out there is doing. I was speaking to a few of the guys before we came in today and now I think I'll definitely be checking out their restaurants and hopefully they'll come to ours too."
The judging panel, which featured a host of burger aficionados and was headed up by celebrity chef Andy Bates, came to a unanimous decision when naming the Venimoo burger as the winner.


text:
Click To Enlarge
Professional Hedge Shears Feature: • High Strength aircraft aluminum handles • Patented center oiler bolt to enhance performance • Replaceable shock absorbing bumper system • Precision carbon steel blades with jaw teeth Blade length: 11¼" Weight: 3lbs. 2oz. Made in the USA Warning: The Shear blades are extremely sharp and can cause severe bodily harm if misused. Under NO conditions cut live electrical cable or wiring. Keep out of reach of children. When not in use, keep shear blades closed.
- Item #: 7-BI-B1100S


text:
Purchase Salopiot
Salopiot Font
Salopiot is a new, ultra-condensed type.
- Salopiot
Salopiot View all glyphs
Lifetime licence for personal and commercial use.
Need Multi-user licenses?
Want to access all fonts?
- Unlimited access to all fonts
- New fonts added daily
- No download limit
- For any commercial project
$19/monthBuy Unlimited Cancel anytime
View font specimen
Add to favorites
Add to favorites
- Including commercial license Every download & purchase includes our premium commercial license. Read about our license.
- Premium technical support Having issues? We're here to provide you with the expert technical support to suit all your needs.
- Crafter friendly Besides standard software such as Illustrator & Photoshop, this font works perfectly with any type of software including Cricut Design Space & Silhouette Studio, MS Word, PicMonkey and many more.
- Unlimited downloads Your purchases are always available online and can be downloaded an unlimited number of times.
Alan Hayward
Follow DesignerView profile
Download thousands of premium fonts Get them all for just $19 Learn more


text:
Food & Drink
Why aren't you taking your vacation?
By Katia Hetter, CNN • Updated 21st November 2013
Why not use those last few vacation days?
Given an average of 14 annual vacation days, Americans left four days on the table over the past year, according to
Expedia.com's 13th annual vacation deprivation study
. That's twice as many as the previous year.
"No one retires wishing they'd spent more time at their desk," said John Morrey, Expedia's vice president and general manager, in a
statement. "There are countless reasons that vacation days go unused -- failure to plan, worry, forgetfulness, you name it. But rested employees are more productive employees, so taking regular vacations may well help the company more than failing to do so."
Workers around the world cite a variety of reasons for not using those days. Some 25% say they like to stockpile days for possible trips in the future. Other reasons include difficulty of scheduling vacations (22%), getting paid for unused days (18%), worry they can't afford a vacation (16%) and failure to plan (15%).
But 8% point the finger not at themselves and instead at the atmosphere of their workplaces, saying they resist using their allotted days off because taking vacation days may be viewed negatively.
These figures and more were determined by Harris Interactive, which conducted this survey online from August 20 to September 12 in North America, Europe, Brazil and the Asia-Pacific region. In all, 24 countries were included, and 8,535 working respondents over age 18 took part. People had to be employed full time, part time or be self-employed.
Americans aren't the most vacation-deprived citizens. That honor goes to both Japan and South Korea. South Koreans take seven out of 10 vacation days, while Japanese workers take seven out of 18 vacation days.
Worldwide, working people get an average of 20 vacation days.
The French top the scale in vacation days, getting 30 off each year and -- get this -- taking all of them. Even so, 90% agree with the phrase, "I feel vacation deprived" despite the fact that they and other Europeans get more vacation time than most others. Even though they have fewer vacation days than the French, some 59% percent of Americans feel vacation deprived.
Norwegians are much less likely to pout about their lack of vacation time: Seventeen percent say they feel vacation deprived. Fewer than half of those from the Netherlands (41%), Denmark (39%) and Mexico (38%) feel the same way.
Once people do vacation, how successful are they at letting go?
Nearly half of those surveyed say they leave work behind "as soon as I leave on vacation," while 20% do when they arrive at their vacation destination. Only 10% can "never" truly relax while away.
Yet 67% of Americans remain connected to their offices via e-mail or voice mail, they say. More than 90% of French, Indian, Thai and Mexican travelers stay connected.
That so many French workers stay connected to the workplace while away may -- or may not -- serve as consolation to others.
A year of the world's
Best Beaches
There's a perfect beach for every week of the year. Join us on a 12-month journey to see them all
Go to the best beaches
Food & Drink
Go to top of page
© 2019 Cable News Network.
Turner Broadcasting System, Inc.
All Rights Reserved. CNN Sans ™ & © 2016 Cable News Network.
Terms of Use
Privacy Policy
About us
Work for us
License Footage
CNN Newsource


text:
from Scratch, (RfS/EL) a program of science-based
teaching techniques, now makes possible normal or better reading.
can't bright dyslectic people read well?
they are miswired to read with the wrong side of the brain. Only the left side can use phonics and keep sequences straight. (ART is not RAT). The dyslectic person relies on his right side which doesn't "do" phonics.
A bridge of tissue in the middle of the brain is out of whack. Reading material that ought to go left goes right as well and the two sides are out of sync. Phonics can cure dyslexia, but only if it is delivered to the correct place at the correct time. Think of penicillin. Yes, it will cure pneumonia, but not if you rub it on your arm. Reading from Scratch works because it provides the critical delivery system: words are sent to the correct area on time.
previously dyslectic student can finally do academic work
that reflects his ability instead of a reading problem.
The Reading from Scratch program, enabling a child
to work happily at his intellectual level, can literally turn
his life around.
To people
who have struggled for years to teach dyslectic students,
the improvements in reading levels shown on the Results
link seem- well, unbelievable, to put it politely. The RfS/EL
program has been so successful, we offer you a full, money-back
Phonics lessons on CD-rom.
here to purchase
Search Our Site:
Dorothy van den Honert just published a new book,
Wiping Out Dyslexia, Musings from my Forty Years of Wiping.
(or order at a bookstore
near you!)
under those circumstances, we have not been able to
help you, and your student has not made much faster
progress than ever before, you may return the material
for a full refund.
many of you know, we put out a short monthly
newsletter that
you can subscribe to below. These are more or less a mixture
of new research, gripes, anecdotes, and teaching tips. If you
have just subscribed and would like to see back issues, they
are now archived on the web. Click on any or all.
Join our e-mail list for newsletters from dyslexia.org!
Please enter your e-mail address here:
contents of this website © Reading From Scratch - All rights
site created and maintained by The Design


text:
A bus exploded in the Israeli city of Tel Aviv just after noon local time.
At least 21 people have been wounded, according to the LA Times.
According to Ofir Gendelman, Prime Minister Netanyahu's official spokesperson, "This was a terrorist attack."
The militant wing of Fatah, the Al Aqsa Martyr Brigade, claimed responsibility for the attacks.
The cease fire agreement between Gaza and Israel was already on the rocks, but coordinated attacks within Israel's borders sends any possibility of a truce more into the distance. Although some Hamas spokesmen seem to believe that the ramped up attacks on places like Tel Aviv will mount pressure on Israel for a truce deal.
Hamas and Fatah have struck an unorthodox truce and decided to unite in an effort to fight back against Israel, despite several years of infighting. Fatah claims it was not a suicide attack, and that the bomber has not been caught.
The LA Times also reports a man was seen running towards the bus, throwing a bag inside and running away.
Though they didn't claim responsibility, Hamas still cheered for the attack. From the LA Times:
In Gaza, Palestinians cheered and celebrated upon hearing the news announced from mosque loudspeakers along with Koranic songs about victory.
"Israel has refused the truce and they want to escalate the violence, so we will have escalate as well," said bank employee Hesham Akram, 27, in central Gaza City. "This way Israelis will feel more insecure so they will give in to our demands for freedom."
More to come. Click here for updates >


text:
This post is presented as part of the University Press Week Blog Tour. November 11-15 is set aside as a week to celebrate the myriad ways university presses contribute to scholarly communication and society at large. Please support our colleagues by exploring more posts in the tour via the links below. For a complete schedule, click here.
If you want to get a great sense of the global reach of the university press and, not incidentally, of the potential of forthcoming publications, you could do worse than observing a few days' worth of foreign rights meetings at the Frankfurt Book Fair.
Perched in a folding chair at a card table in the Princeton University Press booth last month, I watched my colleague Kim Williams, PUP's foreign rights manager (who operates from our office in Oxfordshire), hold 80 meetings with nearly 200 publishers from 22 countries, representing 17 languages around the world. Meetings such as Kim's–going on eight frenetic, exhausting hours a day over the five-day forced march of Frankfurt–comprise the annual ritual wherein the world decides which books and which ideas get dispersed across nations. The word "dissemination" is sometimes used to characterize the mission of university presses. Frankfurt is an example of dissemination of the highest, most sophisticated, most intricately orchestrated kind.
Not only geography, but history matters in the annual translation transaction Olympiad. Kim Williams knows her counterparts at the foreign publishers and has worked with many of them for years. She knows their tastes, interests, and strengths. The experience she brings to the task and the development of these relationships, invest her exchanges with insight and efficiency, providing a kind of multicultural shorthand for conducting the world's book business.
And the game of tongues matters. Over the past ten years the number of Princeton's translation licenses has nearly tripled. Rights deals in Chinese over this period have increased almost tenfold, translations into Japanese have almost tripled, and Korean rights deals have also increased dramatically. And this growth is not limited to Asian markets. We've seen equally strong growth in the number of Turkish, Czech, Brazilian Portuguese, and Spanish translations, among others. Taken all together this increased activity reflects changes in international economic development and national cultural priorities. This upward trend in translation activity will only increase as economic development rises. It would be interesting to know how many of our translated titles win awards and other accolades in their adopted languages.
And much as the annual idea-swap in Frankfurt provides us with a window on the world, it also tells us a lot about ourselves. From a distance, it tells us which subjects "travel" well, yielding valuable insights into list-planning and therefore into editorial acquisitions. From a closer standpoint, it provides a powerfully compelling preview of how a publisher's upcoming list is likely to perform. If three dozen foreign publishers are panting over a particular title, chances are you've got a winner in English as well as around the world in other language markets.
Finally, a week at a rights table in Frankfurt gives a publisher a glimpse into its soul. Just how good are we? Are certain lists as strong as we think they are? Are we current or are we yesterday's news? Do our lists have the three Ds–depth, dimension, and durability–or are we publishing mere ephemera? The five-day stress test in front of the world's hard-bitten foreign publishers answers those questions, sometimes painfully, other times reassuringly.
As the global university press evolves, table talk in Frankfurt will continue to serve as a vital indicator of our impact around the world and our insight into ourselves.
Peter J. Dougherty
Princeton University Press
Click through to check out the covers of various On Bullshit translations.
For more information about Princeton University Press's foreign rights program, please visit http://press.princeton.edu/europe/content/pages/rights.html


text:
Hutchins Dialogue Center
The Hutchins Dialogue Center (HDC), which is a part of the Hutchins Institute for Public Policy (HIPP), is designed as an institutional home for dialogue at Sonoma State University. While dialogue is a multifaceted thing, the HDC focuses on it as an exercise in the exchange of ideas and perspectives. Through Socratic discussion of texts, films, current events and ideas, dialogue can broaden understanding, deepen critical thinking, and simultaneously foster independent thought while strengthening the bonds within a given community.
Core Beliefs of Dialogue:
- Dialogue is Diversity in Action: Dialogue helps people become aware of differences, helping them understand and appreciate them. Through workshops, training, and practice--whether as students, teachers, citizens, or employees--all groups can learn to listen for understanding and find common ground. HDC believes that this level of understanding is the key to optimal group performance.
- Dialogue is a Basic Human Need: Equitable interaction among people is a requirement for the construction of healthy communities. Within a group, there exists many strengths that go untapped and potential that goes unrealized due to conflict, miscommunication, and power struggles. Through optimal learning and improved communication, a greater proportion of these strengths can be accessed and put into action. The attitudes and skills that result from dialogue training create more productive students, citizens and employees in many contexts.
- Dialogue is a Practice: Regular practice of dialogue improves people's quality of work, morale, and reduces stress. Just as regular exercise improves our ability to navigate the physical world and its challenges, dialogue builds the "muscles" and endurance necessary to engage productively in civic life.
Current Projects:
Inter-logue (inter-generational/international): Consolations of Philosophy Dialogue Series
The Aqus Cafe Community Dialogue Series
Past Events, Dialogues and Lectures:
What can we do for you?
The Hutchins Dialogue Center can help you put dialogue in action. Please let us know how we can assist you in designing, implementing dialogue into your classroom, club, organization or any place/situation dialogue can improve communication and understanding! Please contact (707) 664-3300 for more information.
The Hutchins Dialogue Center has found success in practicing diversity and valuing relationship building in collaboration with the Osher Lifelong Learning Institute (OLLI) at the Sonoma State University campus, inviting community members of all ages to our on-campus dialogues. One of our most exciting Interlogue Series has been responding to the question of "what is the good life?" using the Consolations of Philosophy dialogue series by Alain de Botton. Alain de Botton's text The Consolations of Philosophy, as well as the videos from Britain's Channel 4 television series Philosophy: A Guide To Happiness, are a wonderful textual tool for ongoing dialogues attended enthusiastically by people ranging in ages from their late teens to their late seventies.
These dialogues are open to both the campus and the community, and we are hoping to receive more lifelong learners (and SALLI's international language learners) from the wider campus, and from the community at large each week, as well as increasing interest on campus with our student body, faculty and staff. By showing the videos, we make participation in the dialogue possible for those who cannot necessarily afford the book, or may not have the extra time afforded to others to prepare for our sessions.Therefore, each week we all view the video created by Britain's Channel 4 and conduct our discussion after. We create exposure to both the dialogue process and to philosophical theories available to those who might otherwise be denied that access owing to class, status, or circumstance. This particular project has uncovered the importance of diversity beyond race and ethnicity by creating a space and time for people of all ages to come together and share their values and life experience.
The Fall six-week Friday sessions begin on September 14, between 1:00-2:30 PM, in the SSU Multi-Purpose Room (MPR) in the Student Union. There are no charges for participants. Please join us in the GREAT conversation about timeless human issues and concerns!


text:
- Proto 6 Point Sockets are ideal for use on stubborn or damaged fasteners, and also on fasteners made from soft materials.
- The TorquePlus design is a high performance drive configuration which allows for quick and easy socket engagement to the fastener flats, not the corners.
- The TorquePlus configuration employs a radius-corner design, shifting contact area and stress away from the fastener corners and distributing contact stresses over a large area of the socket, minimizing slippage.
- The TorquePlus internal design minimizes fastener rounding, helps to extend fastener life, and allows the user to more easily turn worn, rounded, or rusted fasteners.
|Bolt Clearance Depth
|Drive End Outside Diameter
|12.5 mm
|Drive Size
|Manufacturer Warranty
|Limited Lifetime
|Nut End Hex Depth
|7.1 mm
|Nut End Outside Diameter
|7.9 mm
|Shipping Weight
|0.5 Lbs
|Socket Size
|5 mm
|Tool Weight
|0.03 Lbs
|Typical Application
|Professional, Serious DIY


text:
Here it is. The full text of the: American Taxpayer Relief Act of 2012, AKA the bill to avert the Fiscal Cliff.
Why is it a 157 pages?
Because in addition to the tax and spending stuff, there's all kinds of goodies, like extensions of credits for green energy, and all that stuff in there, that they always put in these things.


text:
A 32-year-old woman died Monday morning after a three-alarm apartment fire at Franconia Apartments in Northeast Baltimore.
The fire broke out shortly after 11 a.m. in the 4400 block of Franconia Drive in the Frankford neighborhood, Baltimore City Fire Department spokesman Ian Brennan said. Units were dispatched at 11:03 a.m., and the blaze was under control at 11:46 a.m., fire officials said.
The victim, who has not been identified, was found dead at 11:24 a.m. If investigators confirm that the woman died because of the blaze, she will be the 19th fire death of the year, Brennan said. Last year, Baltimore hit an all-time low of 12 fire deaths.
There were no other injuries and the cause of the fire is under investigation. BGE was on the scene and the American Red Cross was assisting residents with relocation.
The fire damaged eight apartments as well as the roof of the building adjacent to the apartment where the fire started. While many residents were at work at the time of the fire, some jumped out of windows to escape the smoke and flames.
"I heard a bunch of screaming and yelling," said 27-year-old resident Tanika Murphy, who awoke to the commotion. "My neighbor told me to grab my stuff and that the building was on fire."
Murphy, whose 8-year-old daughter was at school when the fire broke out, said she likely would move into her parents' house for the short term.
Frank Ushery, a repairman driving by the apartment complex when he noticed smoke, went into the building.
"I drove around the lot and saw smoke coming out of a window. I saw a tenant coming out and we went in together," Murphy said.
The pair could not reach anyone, Murphy said, because "the flames were too great."


text:
Ray Romano is back -- but this time, he isn't stuck in suburbia.
The comedian will be the focus of a new reality series on The Golf Channel, the network announced Monday. "The Haney Project" will follow Tiger Woods' swing coach Hank Haney as he helps celebrities with their golf game -- and Romano is the first victim.
"The Haney Project" premiered last season, featuring former NBA star Charles Barkley. It was the second highest-rated program for the network, which started in 1995.
Romano's golf project will air in March, the network said, following Romano as he attempts to finesse his skills on the green.
Romano is best known for starring in the hit show "Everybody Loves Raymond" alongside Patricia Heaton.


text:
Swimming Pool Blog
by Guest Blogger Jackie Roberts, September 15, 2012
Pool Safety For Pets
Reports of children drowning in backyard pools seem to dominate the news during the summer. What you may not hear about as often are the hundreds of stories of dogs that drown in swimming pools. You already take several steps to keep your dog safe and healthy. You feed him good food, give him clean water, administer preventive pet meds to keep him free of pests, and of course, love him.
But have you considered your dog's safety around a swimming pool? Losing a pet is heartbreaking enough without knowing that the death could have been prevented with some simple precautions. Here's how to keep your dog safe from swimming pool accidents, both at home and at a community pool.
Fence in Your Pool
Yes, this can be expensive. But how much is keeping your beloved pet worth? This is an especially important safety precaution if you also have small children. Putting a proper fence with a locking gate around your pool will go a long way to keeping kids and pets out of the pool area. The fence must be high enough that your dog can't jump over it, and if you choose a wood fence over chain link, the planks must be close-enough together that nothing can squeeze between them.
If you move into a home that already has a pool, make installing a fence one of the first projects for your new home. And if you're thinking of having a pool put in, factor the fence into the total cost so it can be installed immediately upon completion of the pool.
Teach Your Dog Where to Exit the Pool
It may surprise you to know that not all dogs can swim. Some breeds like bulldogs may actually sink because of their weight, and because their short legs aren't powerful enough to keep them afloat. But even dogs that can swim can still drown, mostly due to exhaustion. This is especially true for senior dogs that will tire easily. It can be difficult to impossible for a dog of any size to climb out of a pool, and the more they try to climb, and kick to stay afloat, the more tired they get until finally, they just can't swim anymore. The best solution is to teach your dog where the pool stairs are. This is made easier by installing a flag near the stairs.
Because of the shape of dogs' heads and the location of their eyes noses, dogs will keep their heads tilted back to keep water from entering their noses. This means they're essentially looking up, and won't be able to see the side of the pool, much less the stairs. A flag waving near the stairs will be in your dog's field of vision. Also, remember dogs are colorblind, so a bright orange or red flag may not have the effect you intend it to. Instead, choose a black and white checkered flag to best accommodate your dog's colorless vision.
Once you've installed the flag, ease your dog into the water, assuming she's able to swim. If your dog can't swim and will simply sink, put a doggie life jacket on her. Never throw your dog into the pool. This can cause her to panic, and she won't be in a frame of mind for training—just survival. Once she's in, stand near the flag and call to her. As she approaches, she'll eventually feel the stairs under her feet, and will learn she can get out this way. Do this a few times, and give her a treat when she exits the pool. Then try it a few times without standing by the flag, but stay close by in case she can't find her way. It's also a good idea to practice this from time to time to make sure she remembers and will be able to get out on her own if she accidentally ends up in the pool when you're not around.
If your pool has no built in steps, or a swimout area for your dog to exit easily (most dogs can't climb pool ladders), you may want to use a safety ramp for your pets or other animals to be able to exit the pool easily. Skamper Ramp and doggydocks are two such types of products made specifically to address this problem. Poolcenter carries both of these pet pool exit ramps.
Use Immersion Alarms
This is another pool safety precaution that is advisable not just for dogs, but for children as well. An immersion alarm for pets is comprised of two parts—a wearable device that attaches to the pet's collar, and a base station that will sound an alarm with the wearable device is submerged. If you get an immersion alarm, remember to attach it to your dog's collar before you let him into the pool area. Test your device frequently to ensure the batteries are good, and that the alarm is functioning properly.
Never Leave Your Dog Unattended Near the Pool
The number one way to avoid accidents in or near the pool is to keep a close eye on your pets. When the family is gathered around the pool, your dog will no doubt want to be included. After all, she's part of the family, and wants nothing more than to be near her people. If you plan to spend the afternoon near the pool, you can include your dog in the fun—just keep an eye on her. Better yet, keep a doggie life vest on her so that if she does fall—or jump—into the pool, she'll stay afloat until she can get out, or you help her out. You may know your dog can't swim, but your dog doesn't. She may see the kids splashing in the pool, and jump in to get in on the fun, and only then realize she can't swim. Remember, though, leaving a vest on all day in the hot sun can overheat your dog, so if she doesn't get any time in the cool water, give her periodic indoor breaks with the vest off.
Because your pet can overheat, keep fresh drinking water nearby. She may still try to drink pool water, but don't let her do this too much as high levels of chlorine may make her sick if she takes in too much. Above all, never, ever leave your pet unattended in the pool area, even if you've trained her to find the stairs, and even if she has a life jacket on. Accidents are called that for a reason, and you never know when one will occur, even when you've taken every precaution you can think of to prevent it. That's what accidents are—the things you didn't think of, and therefore couldn't prepare for. And remember, pet water safety precautions apply to boats, lakes, and the beach, too.
A swimming pool can provide a lot of fun for family and friends, but it can also be a very dangerous place if safety isn't taken into consideration. Putting precautions in place will only help you—and your dog—enjoy the pool even more.
Jackie is a writer for Security Baron, and loves to help and support the pet community. You can find more tips on Pet Safety at SecurityBaron.com in this article: "All Paws on Deck: How to Keep Your Pets Safe in and Outside the Home".


text:
Next Episode of Dragnet is
not planed. TV Show was canceled.
This long-running show created by Jack Webb features the criminal investigations of police detective Joe Friday. Webb prided himself on making the cases as "realistic" as possible, with many of the cases taken from the files of the LAPD. The series was based on the popular radio series, and subsequently inspired three revivals in the 60s, 1989, and 2003.
Jack Webb(Sgt. Joe Friday)
Barney Phillips(Sgt. Ed Jacobs)
Herb Ellis(Off. Frank Smith)
Barton Yarborough(Sgt. Ben Romero)
Ben Alexander(Off. Frank Smith)
Looks like something went completely wrong!
But don't worry - it can happen to the best of us,
- and it just happened to you.
Please try again later or contact us.


text:
Tijuana site may contain up to 100 dissolved bodies
Authorities searching a vacant property in eastern Tijuana may have found the remains of dozens of drug-war victims gone missing after their corpses were dissolved in lye by a man known as El Pozolero -- the stew maker.
"Stew - it's what's for dinner!"
"We believe that there could be more than 100 bodies dissolved there," said Abel Galvan Gallardo, head of Baja California's organized-crime unit. "There is the total possibility of being able to tell families that their loved one is here."
The search began Tuesday and is likely to last at least into next week, Galvan said Thursday.
By Friday afternoon, federal investigators had discovered 80 human bones and 25 teeth, said Fernando Ocegueda, leader of the group United for the Disappeared of Baja California, which has been collaborating closely with authorities in the excavation effort. The organization represents family members of 280 people, many of whom disappeared at the height of drug violence in Baja California -- from 2007 to 2010.
more disgusting details at the link
Posted by: Frank G 2012-12-01